Regular follow-up appointments are essential during maintenance treatment
Tirzepatide and vomiting Vomiting occurs in 513% of people on tirzepatide across the SURPASS and SURMOUNT trials
Those factors could help explain the benefits seen in heart failure patients, cardiologist Barry Borlaug reported at the meeting and in Nature Medicine
By week 24 (6 months), average total loss is 15 to 18 percent of starting body weight, or 30 to 36 pounds for someone starting at 200 pounds
The therapy led to weight loss in a mouse model of obesity by decreasing food intake and increasing energy expenditure [100]
When to Seek Medical Advice: Patients should contact their healthcare provider immediately for severe or persistent nausea and vomiting leading to dehydration, severe abdominal pain (which may indicate pancreatitis), or severe right upper abdominal pain with or without fever, yellowing of skin/eyes (possible gallbladder disease)